Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia

References

• Curran M, Keating G. Tadalafil. Drugs. 2003;63:2203–2214.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45:339–345.
   PubMed Web of Science ®Google Scholar
• Eardley I, Gentile V, Austoni E, et al. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int. 2004;94:871–877.
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401–1407.
   PubMed Web of Science ®Google Scholar
• Broderick GA, Brock GB, Roehrborn CG, et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010;75:1452–1458.
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Yoshida M, Kim SC, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo-and tamsulosin-controlled 12-week study in Asian men. Int J Urol. 2013;20:193–201.
   PubMed Web of Science ®Google Scholar
• Angulo J, Cuevas P, Fernandez A, et al. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med. 2012;9:2293–2306.
   PubMed Web of Science ®Google Scholar
• Werkstrom V, Svensson A, Andersson KE, et al. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int. 2006;98:414–423.
   PubMed Web of Science ®Google Scholar
• Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8:2746–2760.
   PubMed Web of Science ®Google Scholar
• Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year multicenter comparative. Aldose Reductase Inhibiter Diabetes Complications Trial. Diabetes Care. 2006;29:1538–1544.
   PubMed Web of Science ®Google Scholar
• Uchida K, Kigoshi T, Nakano S, et al. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. Clin Ther. 1995;17:460–466.
   PubMed Web of Science ®Google Scholar
• Kaya E, Sikka SC, Kadowitz PJ, et al. Aging and sexual health: getting to the problem. Aging Male. 2017;20:65–80.
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Profile of serum testosterone levels after application of testosterone ointment (Glowmin) and its clinical efficacy in late-onset hypogonadism patients. J Sex Med. 2008;5:1727–1736.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male. 2010;13:242–246.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomized controlled study. Aging Male. 2011;14:53–58.
   PubMed Web of Science ®Google Scholar
• Du W, Li J, Fan N, et al. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male. 2014;17:107–111.
   PubMed Web of Science ®Google Scholar
• Li J, Shi Q, Wei Q, et al. Re: efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male. 2015;18:71.
   PubMed Web of Science ®Google Scholar
• Leoni LA, Leite GS, Wichi RB, et al. Sildenafil: two decades of benefits or risks? Aging Male. 2013;16:85–91.
   PubMed Web of Science ®Google Scholar
• Condorelli RA, Calogero AE, Di Mauro M, et al. Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study. Aging Male. 2016;19:155–160.
   PubMed Web of Science ®Google Scholar
• Gacci M, Andersson K-E, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–133.
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Hoesl CE, et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS—implications for clinical practice. Andrologia. 2006;38:1–12.
   PubMed Web of Science ®Google Scholar
• Amano T, Earle C, Imao T, et al. Are urge incontinence and aging risk factors of erectile dysfunction in patients with male lower urinary tract symptoms? Aging Male. 2016;19:54–57.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang F, Yu Z, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology. 2017;100:59–64.
   PubMed Web of Science ®Google Scholar
• Brock G, Ni X, Oelke M, et al. Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med. 2016;13:860–875.
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Yamashita A, Arai T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis. 2003;166:303–309.
   PubMed Web of Science ®Google Scholar
• Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19:200–207.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Nagai A, Hara R, et al. Tadalafil for male lower urinary tract symptoms improves endothelial function. Int J Urol. 2017;24:206–210.
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Seki M, et al. The usefulness of vibration perception threshold as a significant indicator for erectile dysfunction in patients with diabetes mellitus at a primary diabetes mellitus clinic. Urol Int. 2011;87:336–340.
   PubMed Web of Science ®Google Scholar